Fixed-dose rasburicase 6 mg for hyperuricemia and tumor lysis syndrome in high-risk cancer patients

Annals of Pharmacotherapy

Volumn 44, Issue 10, 2010, Pages 1529-1537

  Vines, Ashleigh N ^a   Shanholtz, Carl B ^b   Thompson, Jennifer L ^c  

^a UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF MARYLAND MEDICAL CENTER   (United States)

Author keywords

Acute kidney injury; Fixed dose; Hyperuricemia; Rasburicase; Tumor lysis syndrome

Indexed keywords

CREATININE; RASBURICASE; URIC ACID;

ADULT; ARTICLE; CANCER PATIENT; CANCER RISK; CLINICAL ARTICLE; CREATININE BLOOD LEVEL; DRUG EFFICACY; FEMALE; HUMAN; HYPERURICEMIA; KIDNEY INJURY; MALE; PRACTICE GUIDELINE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; SINGLE DRUG DOSE; TUMOR LYSIS SYNDROME; URIC ACID BLOOD LEVEL;

ADULT; AGED; AGED, 80 AND OVER; CREATININE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; GOUT SUPPRESSANTS; HEMATOLOGIC NEOPLASMS; HUMANS; HYPERURICEMIA; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; NEOPLASMS; PHOSPHORUS; PRACTICE GUIDELINES AS TOPIC; RETROSPECTIVE STUDIES; RISK FACTORS; TREATMENT OUTCOME; TUMOR LYSIS SYNDROME; URATE OXIDASE; URIC ACID;

EID: 77957685563     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1P296     Document Type: Article

References (19)

1. Coiffier B, Altman A, Pui CH, Younes A, Cairo MS. Guidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based review. J Clin Oncol 2008;26:2767-78.
2. Cairo MS, Bishop M. Tumour lysis syndrome: new therapeutic strategies and classification. Br J Haematol 2004;127:3-11. (Pubitemid 39331101)
3. Product information. Elitek (rasburicase). Bridgewater, NJ: sanofi-aventis US, October 2009.
4. Tosi P, Barosi G, Lazzaro C, et al. Consensus conference on the management of tumor lysis syndrome. Haematologica 2008;93:1877-85.
5. Harris NL, Jaffe ES, Stein H, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994;84:1361-92.
6. Cortes J, Seiter K, Maziarz RT, et al. Superiority of rasburicase versus allopurinol on serum uric acid control in adult patients with hematological malignancies at risk of developing tumor lysis syndrome: results of a randomized comparative Phase III study. ASH Annual Meeting Abstracts 2008;112:919.
7. Hutcherson DA, Gammon DC, Bhatt MS, Faneuf M. Reduced-dose rasburicase in the treatment of adults with hyperuricemia associated with malignancy. Pharmacotherapy 2006;26:242-7. (Pubitemid 43201871)
8. McDonnell AM, Lenz KL, Frei-Lahr DA, Hayslip J, Hall PD. Single-dose rasburicase 6 mg in the management of tumor lysis syndrome in adults. Pharmacotherapy 2006;26:806-12. (Pubitemid 43807632)
9. Trifilio S, Gordon L, Singhal S, et al. Reduced-dose rasburicase (recombinant xanthine oxidase) in adult cancer patients with hyperuricemia. Bone Marrow Transplant 2006;37:997-1001.
10. Reeves DJ, Bestul DJ. Evaluation of a single fixed dose of rasburicase 7.5 mg for the treatment of hyperuricemia in adults with cancer. Pharmacotherapy 2008;28:685-90.
11. Hummel M, Reiter S, Adam K, Hehlmann R, Buchheidt D. Effective treatment and prophylaxis of hyperuricemia and impaired renal function in tumor lysis syndrome with low doses of rasburicase. Eur J Haematol 2008;80:331-6. (Pubitemid 351347575)
12. Campara M, Shord SS, Haaf CM. Single-dose rasburicase for tumour lysis syndrome in adults: weight-based approach. J Clin Pharm Ther 2009;34:207-13.
13. Knoebel R, Lo M, Crank C. Evaluation of a low, weight-based dose of rasburicase in adult patients for the treatment or prophylaxis of tumor lysis syndrome. J Oncol Pharm Pract 2010 Mar 23 (Epub ahead of print).
14. Shanholtz CB, Ranc B. ICU survival and reversal of organ failure in patients with tumor lysis syndrome receiving urate oxidase (publication page A63). Presented at American Thoracic Society International Conference, Atlanta, GA, May 19, 2002.
15. Bosly A, Sonet A, Pinkerton CR, et al. Rasburicase (recombinant urate oxidase) for the management of hyperuricemia in patients with cancer: report of an international compassionate use study. Cancer 2003;98:1048-54. (Pubitemid 37022107)
16. Cairo MS, Coiffier B, Reiter A, Younes A. Recommendations for the evaluation of risk and prophylaxis of tumour lysis syndrome (TLS) in adults and children with malignant diseases: an expert TLS panel consensus. Br J Haematol 2010;149:578-86.
17. Ten Harkel AD, Kist-Van Holthe JE, Van Weel M, Van der Vorst MM. Alkalinization and the tumor lysis syndrome. Med Pediatr Oncol 1998;31:27-8.
18. Arnold TM, Reuter JP, Delman BS, Shanholtz CB. Use of single-dose rasburicase in an obese female. Ann Pharmacother 2004;38:1428-31. DOI 10.1345/aph.1E002
19. Drug topics red book. Montvale, NJ: Thomson PDR, 2009.